-
Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
•
Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National Medical Products Administration (NMPA) to proceed with a second Phase III study for its antibody drug conjugate (ADC), ESG401. The study will focus on unresectable locally advanced, recurrent, or metastatic PD-L1 negative triple negative breast…
-
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
•
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on its website that three antibody drug conjugates (ADCs) from Chinese pharmaceutical companies are on track to receive breakthrough therapy designations (BTDs) in China. These include Shanghai Escugen’s ESG401, Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692)’s…
-
Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo
•
Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese firm Innolake Biopharma to utilize Escugen’s innovative antibody-drug conjugate (ADC) platform, EZWi-Fit, in the development of ADC products targeting specific antigens selected by Innolake. Under the terms of the agreement, Innolake will employ EZWi-Fit to…
-
Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development
•
Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a strategic partnership with US-based Sidewinder Therapeutics Inc. Under the agreement, Sidewinder has been granted a license to Escugen’s proprietary EZWi-Fit ADC platform, enabling the development of multiple ADC products. This collaboration signifies a significant step…
-
Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401
•
Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first patient in a Phase III clinical study for its candidate drug ESG401. The study is assessing the efficacy of ESG401 in patients with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-)…
-
Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform
•
Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs). Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit…
-
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
•
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop antibody drug conjugates (ADCs) leveraging Escugen’s linker-payload technology, EZWi Fit, and Foreseen’s first-in-class antibodies and targets. This collaboration aims to create ADCs with enhanced drug efficacy and resistance in various tumor models, offering differentiated clinical…
-
Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai Escugen, aimed at advancing the research, development, and manufacturing of antibody-drug conjugates (ADCs). The collaboration extends from late clinical development through to the commercialization phase, with financial details undisclosed. Leveraging Tot Bio’s Expertise in ADC…
-
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
•
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) SKB264, an antibody – drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), has been awarded a breakthrough therapy designation (BTD) for the treatment of locally advanced or metastatic triple – negative breast cancer…
